非酒精性脂肪性肝病与动脉粥样硬化*

doi:10.3969/j.issn.1672-5069.2017.03.003

Abstract

He Fangping. Atherosclerosis in patients with nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 263-266.

[1] Ekstedt M,Franzen LE,Mathiesen UL,et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology,2006,44(4):865-873.
[2] 陈熤. 血小板与动脉粥样硬化. 国际心血管病杂志,2011,38(3):141-144.
[3] 曹一显,李良平. 非酒精性脂肪性肝病与动脉粥样硬化. 国际消化病杂志,2011,31(3):128-131.
[4] Heitzer T,Schlinzig T,Krohn K,et al.Endothelial dysfunction, oxidative stress,and risk of cardiovascular events in patients with coronary artery disease. Circulation,2001,104(22):2673-2678.
[5] 龙盼. 血管内皮功能障碍与动脉粥样硬化. 国际心血管病杂志,2011,38(2):79-81.
[6] Rivera R,Vanaclocha F.Nonalcoholic fatty liver disease and psoriasis. Acta Dermosifiliogr,2010,101(8):657-658.
[7] Ashburn DD,Reed MJ.Gastrointestinal system and obesity. Crit Care Clin,2010,26(4):625-627.
[8] Roitberg GE,Sharkhun OO,Ushakova TI.Non-alcoholic fatty liver disease as an atherosclerosis risk factor. Eksp Klin Gastroenterol,2010,32(7):20-24.
[9] Angulo P,Lindor KD.Insulin resistance and mitochondrial abnormalities in NASH:a cool look into a burning issue. Gastroenterology,2001,120(5):1281-1285.
[10] Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology,2005,42(3):641-649.
[11] 崔晓霞,段桂花,吕井华. 非酒精性脂肪肝与动脉粥样硬化相关的临床研究. 现代保健·医学创新研究,2007,4(11):26-27.
[12] Kessler MA,Levy Y,Roth A,et al.Increased prevalence of NAFLD in patients with acute myoardial infarction independent of BMI. Hepatology,2005,42:623A.
[13] Targher G,Bertolini L,Padovani R,et al.Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med,2006,23(4):403-409.
[14] 高鑫. 非酒精性脂肪性肝病与代谢综合征. 国际内分泌代谢杂志,2006,26(2):73-79.
[15] Las G,Shirihai OS.The role of autophagy in beta-cell lipotoxicity and type 2 diabetes. Diabetes Obes Metab,2010,12(Suppl 2):15-19.
[16] Siddiqui MS,Sterling RK,Luketic VA. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology,2013,145(6):1271-1279. e1-3.
[17] Wang CC,Lin SK,Tseng YF,et al.Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2009,24(8):1411-1416.
[18] Ioannou GN,Weiss NS,Boyko EJ,et al.Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology,2006,43(5):1145-1151.
[19] Schindhelm RK,Dekker JM,Nijpels G.Alanine aminotransferase predicts coronary heart disease events:a 10-year follow-up of the Hoorn Study. Atherosclerosis,2007,191(2):391-396.
[20] Goessling W,Massaro JM,Vasan RS,et al.Aminotransferase levels and 20-year risk of metabolic syndrome,diabetes,and cardiovascular disease. Gastroenterology,2008,135(6):1935-1944, 1944. e1.
[21] Wang Z,Nakayama T.Inflammation,a link between obesity and cardiovascular disease. Mediators Inflamm,2010,2010:535918.
[22] de Ferranti S,Mozaffarian D. The perfect storm:obesity,adipocyte dysfunction,and metabolic consequences. Clin Chem,2008,54(6):945-955.
[23] Bakhai A.Adipokines--targeting a root cause of cardiometabolic risk. QJM,2008,101(10):767-776.
[24] Rane SG,Lee JH,Lin HM.Transforming growth factor-beta pathway:role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev,2006,17(1-2):107-119.
[25] Ludmer PL,Selwyn AP,Shook TL,et al.Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med,1986,315(17):1046-1051.
[26] 高浩源. 血管内皮功能检测的研究进展. 现代诊断与治疗, 2011,22(5):289-291,293.
[27] Bonetti PO,Pumper GM,Higano ST,et al.Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol,2004,44(11):2137-2141.
[28] Reisner Y,Lusky R,Shay-EY,et al.Reproducibility of endothelial function and arterial stiffness assessed using finger peripheral arterial tonometry. Eur Heart J,2008,29(6):255-503.
[29] Selamet TES,Newburger JW,Gauvreau K,et al.Endothelial pulse amplitude testing:feasibility and reproducibility in adolescents. J Pediatr,2009,154(6):901-905.

Atherosclerosis in patients with nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[2]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[5]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[6]	Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.
[7]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[8]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.
[9]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[10]	Yang Jing, Gao Lei.. Fitz-Hugh-Curtis syndrome:a case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 979-980.
[11]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[12]	Zhao Mingying, Li Chunlin.. Hepatic activity grading and fibrosis staging in hepatitis B patients with low serum hepatitis B surface antigen levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 725-728.
[13]	Yan Chenli, Wang Jingjing, Wang Jun.. Severity of coronary artery lesions and risk factors in patients with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 737-740.
[14]	Bing Hao, Li Yiling.. Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 821-824.
[15]	Wang Xinwei, Lyu Ke, Sun Xiao, et al. Effect of selective β3-adrenergic receptor agonist on hepatic oxidative stress and liver fibrosis in rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 384-387.